文献速递生殖医学

利用体外来源生殖细胞恢复男性生育力的路径

The road to restore male fertility using in vitro-derived germ cells.
PubMed 文献 · Hum Reprod Update · 2026-01-01

本文为叙述性综述,总结从人多能干细胞(hPSCs)向男性生殖细胞分化的关键进展与挑战,重点在经转录组和表观遗传验证的人原始生殖细胞样细胞(hPGCLCs)诱导方案。文献显示,近年定义明确的方案可模拟早期胚胎发育,且来自无遗传综合征的不育男性的hiPSCs通常保留早期生殖系定向能力,但hPGCLC之后的成熟仍有限。

要点

  • 定义明确的方案已可诱导体外转录组和表观遗传验证的hPGCLCs。
  • 3D培养系统正用于促进hPGCLCs向可移植SSCs或精子成熟。
  • 无遗传综合征的不育男性hiPSCs通常保留早期生殖系定向能力。

核心结论

  • hiPSCs为缺乏生殖细胞的男性提供了再生生育策略的潜力。
  • 近期定义明确的方案已能诱导体外转录组和表观遗传验证的hPGCLCs。
  • 患者来源hiPSCs的早期生殖系定向能力通常保留,但hPGCLC之后的成熟仍有限。

研究设计与样本

  • 叙述性综述,检索PubMed、Scopus和Web of Science,无时间限制。
  • 排除仅关注女性生殖系分化的研究,仅呈现关键动物研究以保持人类视角。

主要发现

  • 早期从干细胞来源人生殖细胞的研究受低效率、表征不足和缺乏标准化分化方案限制。
  • 近期进展已开发出模拟早期胚胎发育并诱导hPGCLCs的定义明确方案。
  • 当前研究聚焦于在3D培养系统中使hPGCLCs体外成熟,以产生可移植的hiPSC来源SSCs或分化为精子。
  • 来自无遗传综合征的不育风险男性hiPSCs通常保留早期生殖系定向能力。
  • 患者生殖细胞超越hPGCLC状态的成熟尝试仍有限。

临床怎么用

  • 支持从患者获取hiPSCs并定向为hPGCLCs,进而获得hiPSC来源SSCs用于未来治疗。
  • 临床转化前需讨论伦理、监管和社会问题,确保负责任和公平可及。

局限性

  • 患者生殖细胞超越hPGCLC状态的成熟尝试仍有限。
  • 临床 applicable 的生育力恢复策略尚未实现,需进一步突破。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Human-induced pluripotent stem cells (hiPSCs) offer immense potential in reproductive medicine, particularly for males who lack germ cells and cannot achieve biological parenthood through conventional ARTs. Early efforts to derive human germ cells from stem cells were hindered by low efficiency, subpar characterization, and the lack of standardized differentiation approaches. However, recent advancements have led to the development of defined protocols that mimic early embryonic development and allow the specification of transcriptomically and epigenetically validated human primordial germ cell-like cells (hPGCLCs). Current research focuses on maturing hPGCLCs in vitro, particularly within 3D culture systems that resemble their physiological microenvironment, with the aim of producing transplantable hiPSC-derived spermatogonial stem cells (SSCs) or differentiating them to sperm. At the same time, researchers are also testing whether hiPSCs generated from infertile patients can resume germline differentiation. OBJECTIVE AND RATIONALE: This narrative review aimed to summarize the key efforts and remaining challenges in differentiating male germ cells from human pluripotent stem cells (hPSCs), with a particular focus on defined and validated protocols for hPGCLC specification. In parallel, we addressed key safety and ethical considerations that must be accounted for the development of clinical applications. A deeper understanding of the approaching therapeutic use of hiPSCs in reproductive medicine is essential for developing novel regenerative fertility strategies. SEARCH METHODS: PubMed, Scopus, and Web of Science were searched for studies attempting germ cell differentiation from hPSCs using relevant keywords ('stem cells', 'human pluripotent stem cells', 'human embryonic stem cells', 'human induced pluripotent stem cells', 'somatic cell reprogramming', 'infertility', 'germline', 'spermatogenesis', 'germ cells', and 'primordial germ cells'). No time period restriction was established. Studies with an exclusive focus on female germline differentiation were excluded. To maintain a human-focused perspective, only key animal studies are presented. OUTCOMES: The literature reveals a clear segregation among protocols for deriving germ cells from hPSCs, particularly between earlier studies lacking standardized differentiation conditions and characterization, and the most recent, defined protocols having transcriptomic and epigenetic validation against in vivo hPGCs. Moreover, during the last decade, the field has seen remarkable progress, with multiple efforts aimed at maturing hPGCLCs, closely recapitulating late male embryonic germline development. Additionally, hiPSCs derived from male patients at risk of infertility, particularly those without underlying genetic syndromes, generally retain the capacity for early germline commitment. While attempts at maturating patient germ cells beyond the hPGCLC state remain limited, the rapid pace of discovery and refinement in recent years suggests that further breakthroughs, including clinically applicable fertility restoration strategies, are likely to be achieved in the near future. WIDER IMPLICATIONS: The ability to generate hiPSCs from infertile patients and to specify them into hPGCLCs supports the feasibility of obtaining hiPSC-derived SSCs for future therapeutic use. These advances raise important ethical, regulatory, and societal questions that must be actively discussed among researchers, clinicians, policymakers, and the general public to ensure responsible and equitable access to these technologies. REGISTRATION NUMBER: N/A.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Macedo T, Alves-Lopes JP. The road to restore male fertility using in vitro-derived germ cells. Hum Reprod Update. 2026. PMID: 41416641. doi:10.1093/humupd/dmaf029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。